Role of adenosine deaminase in human monocyte differentiation and tumor cell cytotoxicity.
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000241:Adenosine / Q000494:pharmacology; D000243:Adenosine Deaminase / Q000502:physiology*; D058892:Adenosine Deaminase Inhibitors; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D002295:Carcinoma, Transitional Cell / Q000276:immunology; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D006710:Homocysteine / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D008222:Lymphokines / Q000494:pharmacology; D008262:Macrophage Activation / Q000187:drug effects; D009000:Monocytes / Q000166:cytology / Q000201:enzymology* / Q000276:immunology; D009700:Nucleoside Deaminases / Q000502:physiology*; D010587:Phagocytosis / Q000187:drug effects; D013481:Superoxides / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000276:immunology
D058892:Adenosine Deaminase Inhibitors; D008222:Lymphokines; D006710:Homocysteine; D013481:Superoxides; C010192:9-(2-hydroxy-3-nonyl)adenine; C007957:homocysteine thiolactone; D009700:Nucleoside Deaminases; D000243:Adenosine Deaminase; D000225:Adenine; D000241:Adenosine